KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Share-based Compensation (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Share-based Compensation for 15 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 26.45% to $9.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.1 million through Dec 2025, up 19.08% year-over-year, with the annual reading at $33.1 million for FY2025, 19.08% up from the prior year.
  • Share-based Compensation for Q4 2025 was $9.7 million at Supernus Pharmaceuticals, up from $7.8 million in the prior quarter.
  • The five-year high for Share-based Compensation was $9.7 million in Q4 2025, with the low at $4.0 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $6.2 million, with a median of $6.2 million recorded in 2023.
  • The sharpest move saw Share-based Compensation decreased 21.53% in 2022, then soared 58.88% in 2023.
  • Over 5 years, Share-based Compensation stood at $4.0 million in 2021, then rose by 5.57% to $4.3 million in 2022, then soared by 51.26% to $6.4 million in 2023, then rose by 18.42% to $7.6 million in 2024, then grew by 26.45% to $9.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $9.7 million, $7.8 million, and $7.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.